Regulation 1995/541 - Examination of variations to the terms of a marketing authorization granted by a competent authority of a Member State

Please note

This page contains a limited version of this dossier in the EU Monitor.

1.

Current status

This regulation was in effect from March 14, 1995 until September 30, 2003.

2.

Key information

official title

Commission Regulation (EC) No 541/95 of 10 March 1995 concerning the examination of variations to the terms of a marketing authorization granted by a competent authority of a Member State
 
Legal instrument Regulation
Number legal act Regulation 1995/541
CELEX number i 31995R0541

3.

Key dates

Document 10-03-1995
Publication in Official Journal 11-03-1995; OJ L 55 p. 7-14
Effect 14-03-1995; Entry into force Date pub. + 3 See Art 8
End of validity 30-09-2003; Repealed by 32003R1084

4.

Legislative text

Avis juridique important

|

5.

31995R0541

Commission Regulation (EC) No 541/95 of 10 March 1995 concerning the examination of variations to the terms of a marketing authorization granted by a competent authority of a Member State

Official Journal L 055 , 11/03/1995 P. 0007 - 0014

COMMISSION REGULATION (EC) No 541/95 of 10 March 1995 concerning the examination of variations to the terms of a marketing authorization granted by a competent authority of a Member State

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Directive 75/319/EEC of 20 May 1975, on the approximation of provisions laid down by law, regulations or administrative action relating to medicinal products (1), as last amended by Council Directive 93/39/EEC (2) of 14 June 1993, and in particular Article 15 thereof,

Having regard to Council Directive 81/851/EEC of 28 September 1981, on the approximation of legislation of the Member States relating to veterinary medicinal products (3), as last amended by Council Directive 93/40/EEC (4), and in particular Article 23 thereof,

Whereas, appropriate provisions should be adopted for the examination of variations to the terms of a marketing authorization of medicinal products which have benefited from the procedures of mutual recognition foreseen in Articles 7 and 7a of Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (5), as last amended by Directive 93/39/EEC, in Article 9 (4) of Council Directive 75/319/EEC or in Articles 8, 8a and 17 (4) of Council Directive 81/851/EEC, and medicinal products for which there has been a referral to the procedures foreseen by Articles 13 and 14 of Directive 75/319/EEC or Articles 21 and 22 of Directive 81/851/EEC;

Whereas, these provisions should also apply to the examination of applications to vary the terms of a marketing authorization which had been considered within the scope of application of Council Directive 87/22/EEC of 22 December 1986 on the approximation of national measures relating to the placing on the market of high technology medicinal products, particularly those derived from biotechnology (6);

Whereas, it is appropriate to include a notification system or administrative procedures concerning minor variations for which it is necessary to precisely define minor variations;

Whereas, moreover, it is necessary to distinguish from amongst those variations which do not qualify as minor variations, those which must be considered to so fundamentally alter the marketing authorization, particularly from the point of view of the quality, safety or efficacy of a medicinal product, that a new application for a marketing authorization would be required;

Whereas, the provisions of this Regulation are in accordance with the opinion of the Standing Committee on Medicinal Products for Human use and the Standing Committee on Veterinary Medicinal Products,

HAS ADOPTED THIS REGULATION:

Scope and definitions

Article 1

  • 1. 
    This Regulation lays down the procedure for the examination of applications for variations to the terms of a marketing authorization of medicinal products which have been considered within the scope of application of Directive 87/22/EEC, of medicinal products having benefited from the procedures of mutual recognition foreseen in Articles 7 and 7a of Directive 65/65/EEC, Article 9 (4) of Directive 75/319/EEC or Articles 8, 8a and 17 (4) of Directive 81/851/EEC, and medicinal products for which there has been a referral to the procedures foreseen by Articles 13 and 14 of Directive 75/319/EEC or Articles 21 and 22 of Directive 81/851/EEC.
  • 2. 
    This Regulation does not impede the marketing authorization holder(s) from taking provisional urgent safety restrictions in the event of risk to public or animal health. The holder(s)...

More

This text has been adopted from EUR-Lex.

 

6.

Sources and disclaimer

For further information you may want to consult the following sources that have been used to compile this dossier:

This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.

 

7.

Full version

This page is also available in a full version containing de geconsolideerde versie, the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and finally the related cases of the European Court of Justice.

The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.

8.

EU Monitor

The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.